For metastatic BC, standard therapy options include targeted approaches such as CDK4/CDK6 inhibitors, PI3K and PARP inhibitors and anti-PD-L1 immunotherapy, depending on tumor subtype and molecular profile (29–32). Here, CD274 is linked to breast cancer.